Jefferies lowered the firm’s price target on Boston Scientific (BSX) to $100 from $110 and keeps a Buy rating on the shares following first quarter results. While Q1 was better than expected, new issues arose in urology and cardiac rhythm management, Watchman slowed and Boston Scientific lowered its 2026 guidance, the firm told investors in a research note. Jefferies added that it continues to view the company as undervalued.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $80 from $90 at BTIG
- Morning News Wrap-Up, 4/22/26: Today’s Biggest Stock Market Stories!
- Early notable gainers among liquid option names on April 22nd
- Here’s Why Boston Scientific Stock (BSX) Is Up 10% Today
- Why Is Vanguard S&P 500 ETF (VOO) Up Today, 4/22/2026?